Search results (257)
« Back to PublicationsChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
Ebrahimi N. et al, (2026), Vaccine, 88
Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.
Peralta Alvarez MP. et al, (2026), Vaccines (Basel), 14
Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Study.
Alsaleh G. et al, (2026), Aging Cell, 25
Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms.
Bissett C. et al, (2026), J Exp Med, 223
Time to tackle vaccine-HLA associations with artificial intelligence.
Mentzer AJ. et al, (2026), Lancet Infect Dis, 26
Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.
Siu JHY. et al, (2025), EBioMedicine, 122
Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria.
Limon G. et al, (2025), Emerg Infect Dis, 31, 1738 - 1746
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines.
Murray SM. et al, (2025), Sci Immunol, 10
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Amini A. et al, (2025), Sci Immunol, 10
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).
Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9
Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.
McLean RK. et al, (2025), NPJ Vaccines, 10